The results of CardinALS showed utreloxastat failed to meet its main and secondary goals, including several disease-related ...

Columnist Dagmar Munn has managed the shift to a rollator, scooter, and other assistive devices that help her live a better ...

Neuralink's brain-computer interface will be tested in Canada, with Toronto's University Health System seeking patients for ...

The Phase 1 trial ANQUR, now testing two new doses of the ALS therapy QRL-201, is enrolling patients at 12 sites in Canada ...

Scientists studied 188 people related to someone with ALS caused by a C9ORF72 mutation to identify markers of disease risk in ...

Columnist Dagmar Munn has a Santa wish list for her outings over the holidays: accessible restrooms and good cutlery among ...

Widetrial is supporting an expanded access program (EAP) to bring MN-166 (ibudilast) to ALS patients ineligible for clinical ...

A grant from the ALS Association will fund an early-stage clinical trial to test Tiziana's foralumab nasal spray in 20 ALS ...

The Converge platform validated as many as 83% of its treatment targets in disease models, a higher success rate than usual ...

The world's largest ALS patient-derived stem cell and biodata repository is now available to researchers globally.

Although she did everything possible to learn about ALS, columnist Juliet Taylor says the disease often left her feeling ...

Ractigen's RAG-21, a treatment for ALS linked to mutations in the FUS gene, has been granted orphan drug designation in the U ...